ARTICLE | Clinical News
RCN-01303: Began Phase I trial
April 9, 2001 7:00 AM UTC
Receptron Inc., Mountain View, Calif. Product: RCN-01303 Business: Cancer Therapeutic category: Receptor agonist Target: Thrombopoietin (TPO) receptors Description: Peptide TPO activity enhancer Indic...